Spotlight - GlaxoSmithKline - Cerebras

GlaxoSmithKline

Taking advantage of new kinds of neural network models to accelerate drug discovery

GlaxoSmithKline is a pharmaceutical company dedicated to improving the quality of human life by helping people do more, feel better, and live longer. Innovation is at the core of their mission and in order to take advantage of new kinds of neural network models for drug discovery, they realized they needed an AI solution with larger memory and throughput. With a CS-1 system, they are increasing the complexity of their models, while decreasing training time by 80x.

"Last year we generated more data in three months than in our entire 300-year history. With the Cerebras CS-1, we have been able to increase the complexity of the encoder models that we can generate, while decreasing their training time by 80x."

Kim Branson

SVP Global Head of AI and ML @ GlaxoSmithKline

Kim Branson, SVP Global Head of AI and ML at GSK, discusses AI for drug discovery and the Cerebras partnership

See how GlaxoSmithKline is using the Cerebras System

GlaxoSmithKline and Cerebras are Advancing the State of the Art in AI for Drug Discovery

GSK published findings: EBERT models for epigonomic research were 160 times faster on the CS-1 than on a GPU

How AI Is Aiming at the Bad Math of Drug Development

Read News Article

Unconventional collaborations between biopharma and tech are starting to take off

Read News Article

Unconventional collaborations between biopharma and tech are starting to take off

Read News Article

Additional Resources

Customer StoriesHealth and Pharma